GlycoMimetics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

GlycoMimetics wird ein Gewinn- und Umsatzwachstum von 10.9% bzw. 72.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 27.8% pro Jahr wachsen soll.

Wichtige Informationen

10.9%

Wachstumsrate der Gewinne

27.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	72.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07

The Investment Case For GlycoMimetics

Nov 17

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:GLYC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1	-25	-36	-6	3
12/31/2025	4	-31	-37	-8	3
12/31/2024	N/A	-32	-38	-31	3
6/30/2024	0	-39	-36	-36	N/A
3/31/2024	0	-37	-34	-34	N/A
12/31/2023	0	-37	-35	-35	N/A
9/30/2023	N/A	-38	-35	-35	N/A
6/30/2023	N/A	-37	-35	-35	N/A
3/31/2023	0	-42	-44	-44	N/A
12/31/2022	0	-47	-47	-46	N/A
9/30/2022	0	-54	-51	-51	N/A
6/30/2022	0	-63	-60	-60	N/A
3/31/2022	0	-64	-57	-57	N/A
12/31/2021	1	-63	-58	-57	N/A
9/30/2021	1	-62	-54	-54	N/A
6/30/2021	2	-58	-49	-49	N/A
3/31/2021	2	-58	-50	-50	N/A
12/31/2020	10	-51	-39	-39	N/A
9/30/2020	10	-50	-42	-42	N/A
6/30/2020	9	-50	-44	-44	N/A
3/31/2020	9	-51	-41	-41	N/A
12/31/2019	N/A	-58	-52	-52	N/A
9/30/2019	N/A	-57	-49	-49	N/A
6/30/2019	N/A	-55	-46	-46	N/A
3/31/2019	N/A	-51	-48	-47	N/A
12/31/2018	N/A	-48	-43	-43	N/A
9/30/2018	N/A	-44	-42	-42	N/A
6/30/2018	N/A	-40	-38	-38	N/A
3/31/2018	N/A	-37	N/A	-31	N/A
12/31/2017	N/A	-33	N/A	-30	N/A
9/30/2017	N/A	-32	N/A	-27	N/A
6/30/2017	0	-32	N/A	-29	N/A
3/31/2017	0	-32	N/A	-30	N/A
12/31/2016	0	-32	N/A	-30	N/A
9/30/2016	0	-32	N/A	-31	N/A
6/30/2016	0	-32	N/A	-10	N/A
3/31/2016	20	-13	N/A	-9	N/A
12/31/2015	20	-13	N/A	-8	N/A
9/30/2015	20	-11	N/A	-7	N/A
6/30/2015	20	-11	N/A	-26	N/A
3/31/2015	15	-13	N/A	-10	N/A
12/31/2014	15	-11	N/A	-4	N/A
9/30/2014	15	-8	N/A	-4	N/A
6/30/2014	15	-5	N/A	-2	N/A
3/31/2014	0	-16	N/A	-14	N/A
12/31/2013	4	-11	N/A	-16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GLYC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: GLYC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: GLYC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: GLYCDie Einnahmen des Unternehmens (71.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: GLYCDie Einnahmen des Unternehmens (71.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von GLYC in 3 Jahren voraussichtlich hoch sein wird

GlycoMimetics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Price target decreased by 31% to US$5.50

No longer forecast to breakeven

Price target decreased by 35% to US$5.50

Forecast to breakeven in 2025

Price target decreased to US$8.50

Recent updates

Glycomimetics Announces to Reduce Its Workforce by Approximately 80%

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Receives Non-Compliance letter from Nasdaq Regarding Listing Rule 5450(a)(1)

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

New major risk - Financial position

New major risk - Revenue and earnings growth

New minor risk - Profitability

No longer forecast to breakeven

GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

New minor risk - Profitability

GlycoMimetics Can Become A Game Changer In Blood Cancers

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Price target decreased by 31% to US$5.50

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Senior VP & Chief Medical Officer recently bought US$90k worth of stock

GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

New minor risk - Market cap size

GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

No longer forecast to breakeven

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Price target decreased by 35% to US$5.50

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Chief Medical Officer recently bought US$248k worth of stock

GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Insider recently bought US$53k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

GlycoMimetics has a new Chief Medical Officer

Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021)

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$8.50

GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021)

Insufficient new directors

GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022

GlycoMimetics, Inc., Annual General Meeting, May 18, 2022

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Independent Director recently bought US$82k worth of stock

Price target increased to US$14.50

GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Price target increased to US$14.50

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index

Consensus forecasts updated

GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Senior VP of Clinical Development & Chief Medical Officer has left the company

Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML